The combined use of sodium-glucose transport protein 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists may offer notable benefits for optimizing cardiovascular and renal outcomes in patients with diabetes, according to findings from a collaborative meta-analysis of trials from the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium (SMART-C). A total of 12 SMART-C trials encompassing …
Research in animals has shown that the diabetes drug dulaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist may reduce symptoms of depression. A new study published in Brain and Behavior reveals the mechanisms that are likely involved. By conducting a range of tests in mice treated with and without dulaglutide, investigators confirmed the effects …
30 Nov 2023 — As the prevalence of type 2 diabetes continues to rise globally, so do efforts to find effective and natural solutions. Nutrition Insight gathers industry insights by speaking to Valio, Ingredients by Nature, Nutrartis and PharmaLinea. The experts discuss dairy’s impact on diabetes risk, herbal alternatives and scientifically proven …
New phase 2 data presented at The Liver Meeting 2023 from the American Association for the Study of Liver Diseases (AASLD) in Boston this weekend showed triple agonist therapy retatrutide resolved early-stage fatty liver disease in nearly 90% of patients with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). The findings, presented by Arun J. …